Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
BioCentury This Week
00:00
I L to as a Cancer Amutitherapy
We've lifted the pipe line since two thousand 15 of a set of next generation check bord targets. And it's been growing rapidly over the last few years, especially since we've started to see the tigit data and e lag three ata. Even those that have had trouble and the set backs, are, for the most part, continuing to see development through the phases and more programms added to the pipeplan. Stephen loren, i want to turn to you talk us through this a little bit.
Transcript
Play full episode
